Skip to content

WHO Accelerated Platform for Novel Regimens

  • Adam Ortega

The WHO Global TB Program's Accelerator Platform for Novel TB Regimens held its 12th meeting to examine the four-month HPMZ (isoniazid, rifapentine, moxifloxacin, pyrazinamide) regimen for tuberculosis treatment, covering country experiences, implementation tools, and next steps for rollout. Despite the World Health Organization's (WHO) 2022 recommendation, implementation has remained limited, with challenges such as high pill burden and medicine costs cited as potential barriers.

Read more

What TB Treatment Advocates Need to Know about aDSM/PV

  • Jason Kirk

Join TAG on April 16 at 8:30 a.m. ET for a practical webinar on drug safety monitoring in TB treatment. Learn how to identify side effects, support patient safety, and understand pharmacovigilance in the context of newer, all-oral DR-TB regimens.

Read more

Advocacy for TB Scientists

  • Jason Kirk

In this interactive November 2025 webinar, TAG and our partners highlighted some of the federal policies, executive orders, and funding cuts that have been impacting TB research since the beginning of 2025.

Read more
Back To Top